RIKEN VITAMIN CO.,LTD. Q4 FY2026 earnings call

• Company Overview

  • Riken Vitamin is a mid-sized food manufacturer listed on the Tokyo Prime Market, with 76 years of operating history. Prior fiscal year total revenue hit a record high of 95.5 billion yen, with a 9.1% operating margin.
  • While known to consumers for hit consumer products such as Riken Non-Oil Aojiso Dressing and Fuero Wakame-chan, over 86% (more than 80%) of total revenue comes from BtoB sales of raw materials for food, pharmaceuticals, and chemical products.
  • The firm's core founding mission is to contribute to public health through effective utilization of natural resources and proprietary technology, with all product lines developed organically originating from early vitamin A production technology.

• Recent Historical and Financial Performance

  • All performance targets for the previous mid-term management plan were achieved, with operating profit targets hit in the second year of the plan. The final year ROE rose to 12.1%, driven by policy holding share reductions that boosted net income.
  • 2024 fiscal year performance significantly outperformed initial plans, driven by domestic business offsetting a slight overseas downturn. Appropriate price adjustments and low-margin product rationalization drove the outperformance.
  • Current valuation is discounted: recent share price trades at a PBR of 0.9x and PER of less than 8x, half the average PER for the Prime Market food sector. ROE is well above peer averages, and management sees the stock as undervalued.

• Strategic Priorities

  • Core goal is to reach a 100 billion yen market capitalization, and sustain PBR above 1x, by improving core operating profitability, strengthening balance sheet management, improving non-financial disclosures, and expanding investor outreach.
  • Domestic Food: Focus on developing and growing new market-creating consumer products, activating existing product lines, and expanding proposals for the growing ready-to-eat/central kitchen/frozen meal markets, while addressing raw material and cost challenges through targeted price adjustments.
  • Domestic Chemicals: Concentrate R&D and sales resources on the firm's unique plant-derived improved agent position, and pursue expansion in both domestic and overseas markets.
  • Overseas: Designated as a core growth driver. Management is strengthening back-office support and regular domestic talent rotation to accelerate growth, with a focus on expanding food improvement agents across Southeast Asia, China, and North America. A new food improvement agent factory started operations in Tianjin, China in May, and pork extract capacity is being expanded in North America to serve the growing US ramen market.

• Sustainability Initiatives

  • Food: Riken Vitamin is developing heat-tolerant seaweed seedlings and supporting seaweed aquaculture to address declining production from climate change and producer aging, and is conducting long-term research on blue carbon sequestration. The firm also uses environmentally friendly packaging and partners on sustainable ingredient development.
  • Improved Agents: The firm contributes to food loss reduction through its freshness preservation technology, and sees long-term growth opportunities for its plant-derived chemical improvement agents that replace petroleum-based raw materials.

• Capital Allocation

  • Total planned capital expenditure for Mid-term Plan 2027 is 250 billion yen, with 130 billion yen allocated domestically and 120 billion yen allocated to overseas, focusing on improvement agents. Capital spending covers labor-saving investment to address labor shortages, equipment updates, and capacity expansion for high value-added products overseas.
  • The dividend payout ratio has been raised from 30% to 40%, with a planned current year dividend of 110 yen per share (up 16 yen year-over-year), and will conduct agile treasury share purchases.

1. Domestic Food Business: Is the highest profit contributor to the firm, accounting for 14% of total revenue from consumer home products, with the majority of segment revenue coming from BtoB food products (seasonings, processed/dried/frozen seaweed, extract products for food service and processed food manufacturers).
2. Modified Products (Improvement Agents): Accounts for approximately 50% of total firm revenue. This segment includes food improvement agents (emulsifiers, vitamins, pigments, where Riken Vitamin holds leading market share for glycerin fatty acid ester (30% of the total emulsifier market) and gardenia yellow pigment) and chemical product improvement agents (anti-fog agents, plasticizers, antistatic agents for plastics/rubber, thickeners for hand soap built on food improvement agent technology).
3. Healthcare: Holds over 40% market share for vitamin E in Japan. Key products include mixed vitamins, crocetin (raw material for functional labeled foods), and microcapsule technology for pharmaceuticals and food to stabilize active ingredients and preserve freshness. Riken Vitamin also supplies raw materials for protein powder and complete nutritional foods.
4. Overseas Business: Accounts for 25% of total firm revenue. The United States represents approximately 10% of total overseas revenue, half of which is exported Malaysian-sourced improvement agents and half is locally produced pork extract.

• 10-year long-term vision targets: 135 billion yen in total revenue, 13.5 billion yen in operating profit, 10% operating margin, and 10-12% ROE, with a 7-8% cost of capital.
• Mid-term Management Plan 2027 (covering the next 3 years) targets: 110 billion yen in total revenue, 10 billion yen in operating profit, and 10%+ ROE. The two core mid-term priorities are strengthening a sustainable domestic profit base and building a new foundation for future overseas growth.
• U.S. tariff impacts are currently not incorporated into the plan, as the impact remains highly uncertain.

• Shrinking domestic population and stagnating domestic market growth challenge domestic sales growth.
• Climate change increases raw material procurement risk, particularly for the firm's large base of natural raw materials. Seaweed aquaculture production is already declining due to higher water temperatures and producer aging.
• Persistently rising non-material costs including labor, logistics, and energy add margin pressure. BtoC price adjustments are constrained by demand elasticity: excessive price increases for seaweed can drive consumers to substitute vegetables and hurt sales volume.
• U.S. tariffs of over 40% on exported Malaysian improvement agents to the U.S. could negatively impact this business, which accounts for 10% of total overseas revenue. Indirectly, broad trade tariffs could slow global growth and reduce demand for the firm's high value-added products.
• Geopolitical and trade conflicts can disrupt raw material procurement from global suppliers, increasing supply chain risk.

Q: Can Riken Vitamin continue to implement further price increases for domestic food products to improve profitability? / A: Management notes that while raw material price increases have largely been passed through in recent years, now rising labor, logistics, and energy costs are the main margin pressure. BtoB product price adjustments will continue to appropriately pass through higher costs, but BtoC price increases are constrained by demand sensitivity. Especially for seaweed, excessive price hikes will push consumers to substitute cheaper alternatives like vegetables, so management will proceed carefully while maintaining a core policy of passing through higher costs.

Q: What is the rate of new hit product generation, and does Riken Vitamin have a target hit rate after its product development reorganization? / A: Management confirms that the product development reorganization over the past 3 years has increased the frequency of hit products compared to prior periods. Hit product probability remains low overall, consistent with industry norms, but aligning development with market demand combined with Riken Vitamin's existing technical strengths has improved the hit rate. The main challenge now is scaling successful new products, and management continues to prioritize new product and existing product improvement for both BtoC and BtoB segments.

Q: What type of M&A does Riken Vitamin currently anticipate? / A: After the 2020 earnings decline caused by issues with an acquired Chinese subsidiary, the prior mid-term plan ruled out M&A activity. Now management acknowledges that inorganic growth is needed to complement organic expansion, so the firm is building internal capabilities to pursue small to mid-sized suitable targets, with no specific deals to announce at this time.

Q: What is the current outlook for raw material procurement amid global inflation and supply chain volatility? / A: So far, foreign exchange and inflation impacts have been limited. To mitigate supply risks, Riken Vitamin increases inventory for vulnerable raw materials and pursues expanded origin diversification. Management still expects procurement challenges to grow in the future, but current measures are sufficient to maintain stable supply.